KarisBio, Inc.
- Biotech or pharma, therapeutic R&D
First-in-class hiPSC derived Endothelial cell therapy for cardiovascular disease
We are a clinical-stage biotech company developing regenerative cell therapies for cardiovascular disease. Our iPSC-derived endothelial cell therapy is in Phase I trials for PAD—the world’s first clinical study of its kind. We are also advancing directly reprogrammed endothelial cells (rECs) as next-generation vascular therapeutics in collaboration with Emory University.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}